1 Orphan Indication Treatment Market Overview 1.1 Product Overview and Scope of Orphan Indication Treatment 1.2 Orphan Indication Treatment Segment by Type 1.2.1 Global Orphan Indication Treatment Sales Growth Rate Comparison by Type (2022-2028) 1.2.2 Biologics 1.2.3 Non-Biologics 1.3 Orphan Indication Treatment Segment by Application 1.3.1 Global Orphan Indication Treatment Sales Comparison by Application: (2022-2028) 1.3.2 Hospital Pharmacy 1.3.3 Retail Pharmacy 1.3.4 Online Sales 1.4 Global Orphan Indication Treatment Market Size Estimates and Forecasts 1.4.1 Global Orphan Indication Treatment Revenue 2017-2028 1.4.2 Global Orphan Indication Treatment Sales 2017-2028 1.4.3 Orphan Indication Treatment Market Size by Region: 2017 Versus 2021 Versus 2028 2 Orphan Indication Treatment Market Competition by Manufacturers 2.1 Global Orphan Indication Treatment Sales Market Share by Manufacturers (2017-2022) 2.2 Global Orphan Indication Treatment Revenue Market Share by Manufacturers (2017-2022) 2.3 Global Orphan Indication Treatment Average Price by Manufacturers (2017-2022) 2.4 Manufacturers Orphan Indication Treatment Manufacturing Sites, Area Served, Product Type 2.5 Orphan Indication Treatment Market Competitive Situation and Trends 2.5.1 Orphan Indication Treatment Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Orphan Indication Treatment Players Market Share by Revenue 2.5.3 Global Orphan Indication Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Orphan Indication Treatment Retrospective Market Scenario by Region 3.1 Global Orphan Indication Treatment Retrospective Market Scenario in Sales by Region: 2017-2022 3.2 Global Orphan Indication Treatment Retrospective Market Scenario in Revenue by Region: 2017-2022 3.3 North America Orphan Indication Treatment Market Facts & Figures by Country 3.3.1 North America Orphan Indication Treatment Sales by Country 3.3.2 North America Orphan Indication Treatment Revenue by Country 3.3.3 United States 3.3.4 Canada 3.4 Europe Orphan Indication Treatment Market Facts & Figures by Country 3.4.1 Europe Orphan Indication Treatment Sales by Country 3.4.2 Europe Orphan Indication Treatment Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Orphan Indication Treatment Market Facts & Figures by Region 3.5.1 Asia Pacific Orphan Indication Treatment Sales by Region 3.5.2 Asia Pacific Orphan Indication Treatment Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 China Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.6 Latin America Orphan Indication Treatment Market Facts & Figures by Country 3.6.1 Latin America Orphan Indication Treatment Sales by Country 3.6.2 Latin America Orphan Indication Treatment Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Orphan Indication Treatment Market Facts & Figures by Country 3.7.1 Middle East and Africa Orphan Indication Treatment Sales by Country 3.7.2 Middle East and Africa Orphan Indication Treatment Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Orphan Indication Treatment Historic Market Analysis by Type 4.1 Global Orphan Indication Treatment Sales Market Share by Type (2017-2022) 4.2 Global Orphan Indication Treatment Revenue Market Share by Type (2017-2022) 4.3 Global Orphan Indication Treatment Price by Type (2017-2022) 5 Global Orphan Indication Treatment Historic Market Analysis by Application 5.1 Global Orphan Indication Treatment Sales Market Share by Application (2017-2022) 5.2 Global Orphan Indication Treatment Revenue Market Share by Application (2017-2022) 5.3 Global Orphan Indication Treatment Price by Application (2017-2022) 6 Key Companies Profiled 6.1 Bristol-Myers Squibb 6.1.1 Bristol-Myers Squibb Corporation Information 6.1.2 Bristol-Myers Squibb Description and Business Overview 6.1.3 Bristol-Myers Squibb Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.1.4 Bristol-Myers Squibb Orphan Indication Treatment Product Portfolio 6.1.5 Bristol-Myers Squibb Recent Developments/Updates 6.2 Roche 6.2.1 Roche Corporation Information 6.2.2 Roche Description and Business Overview 6.2.3 Roche Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.2.4 Roche Orphan Indication Treatment Product Portfolio 6.2.5 Roche Recent Developments/Updates 6.3 Novartis 6.3.1 Novartis Corporation Information 6.3.2 Novartis Description and Business Overview 6.3.3 Novartis Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.3.4 Novartis Orphan Indication Treatment Product Portfolio 6.3.5 Novartis Recent Developments/Updates 6.4 Johnson & Johnson 6.4.1 Johnson & Johnson Corporation Information 6.4.2 Johnson & Johnson Description and Business Overview 6.4.3 Johnson & Johnson Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Johnson & Johnson Orphan Indication Treatment Product Portfolio 6.4.5 Johnson & Johnson Recent Developments/Updates 6.5 Pfizer 6.5.1 Pfizer Corporation Information 6.5.2 Pfizer Description and Business Overview 6.5.3 Pfizer Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.5.4 Pfizer Orphan Indication Treatment Product Portfolio 6.5.5 Pfizer Recent Developments/Updates 6.6 Amgen 6.6.1 Amgen Corporation Information 6.6.2 Amgen Description and Business Overview 6.6.3 Amgen Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.6.4 Amgen Orphan Indication Treatment Product Portfolio 6.6.5 Amgen Recent Developments/Updates 6.7 Sanofi 6.6.1 Sanofi Corporation Information 6.6.2 Sanofi Description and Business Overview 6.6.3 Sanofi Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Sanofi Orphan Indication Treatment Product Portfolio 6.7.5 Sanofi Recent Developments/Updates 6.8 AstraZeneca 6.8.1 AstraZeneca Corporation Information 6.8.2 AstraZeneca Description and Business Overview 6.8.3 AstraZeneca Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.8.4 AstraZeneca Orphan Indication Treatment Product Portfolio 6.8.5 AstraZeneca Recent Developments/Updates 6.9 Takeda 6.9.1 Takeda Corporation Information 6.9.2 Takeda Description and Business Overview 6.9.3 Takeda Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.9.4 Takeda Orphan Indication Treatment Product Portfolio 6.9.5 Takeda Recent Developments/Updates 6.10 Vertex Pharmaceuticals 6.10.1 Vertex Pharmaceuticals Corporation Information 6.10.2 Vertex Pharmaceuticals Description and Business Overview 6.10.3 Vertex Pharmaceuticals Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.10.4 Vertex Pharmaceuticals Orphan Indication Treatment Product Portfolio 6.10.5 Vertex Pharmaceuticals Recent Developments/Updates 6.11 AbbVie 6.11.1 AbbVie Corporation Information 6.11.2 AbbVie Orphan Indication Treatment Description and Business Overview 6.11.3 AbbVie Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.11.4 AbbVie Orphan Indication Treatment Product Portfolio 6.11.5 AbbVie Recent Developments/Updates 6.12 Biogen 6.12.1 Biogen Corporation Information 6.12.2 Biogen Orphan Indication Treatment Description and Business Overview 6.12.3 Biogen Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.12.4 Biogen Orphan Indication Treatment Product Portfolio 6.12.5 Biogen Recent Developments/Updates 6.13 Eli Lilly 6.13.1 Eli Lilly Corporation Information 6.13.2 Eli Lilly Orphan Indication Treatment Description and Business Overview 6.13.3 Eli Lilly Orphan Indication Treatment Sales, Revenue and Gross Margin (2017-2022) 6.13.4 Eli Lilly Orphan Indication Treatment Product Portfolio 6.13.5 Eli Lilly Recent Developments/Updates 7 Orphan Indication Treatment Manufacturing Cost Analysis 7.1 Orphan Indication Treatment Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Orphan Indication Treatment 7.4 Orphan Indication Treatment Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Orphan Indication Treatment Distributors List 8.3 Orphan Indication Treatment Customers 9 Orphan Indication Treatment Market Dynamics 9.1 Orphan Indication Treatment Industry Trends 9.2 Orphan Indication Treatment Market Drivers 9.3 Orphan Indication Treatment Market Challenges 9.4 Orphan Indication Treatment Market Restraints 10 Global Market Forecast 10.1 Orphan Indication Treatment Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Orphan Indication Treatment by Type (2023-2028) 10.1.2 Global Forecasted Revenue of Orphan Indication Treatment by Type (2023-2028) 10.2 Orphan Indication Treatment Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Orphan Indication Treatment by Application (2023-2028) 10.2.2 Global Forecasted Revenue of Orphan Indication Treatment by Application (2023-2028) 10.3 Orphan Indication Treatment Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Orphan Indication Treatment by Region (2023-2028) 10.3.2 Global Forecasted Revenue of Orphan Indication Treatment by Region (2023-2028) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Orphan Indication Treatment Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million) Table 2. Global Orphan Indication Treatment Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million) Table 3. Global Orphan Indication Treatment Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Orphan Indication Treatment Market Competitive Situation by Manufacturers in 2021 Table 5. Global Orphan Indication Treatment Sales (K Units) of Key Manufacturers (2017-2022) Table 6. Global Orphan Indication Treatment Sales Market Share by Manufacturers (2017-2022) Table 7. Global Orphan Indication Treatment Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Orphan Indication Treatment Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Orphan Indication Treatment Average Price (US$/Unit) of Key Manufacturers (2017-2022) Table 10. Manufacturers Orphan Indication Treatment Manufacturing Sites and Area Served Table 11. Manufacturers Orphan Indication Treatment Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Orphan Indication Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Orphan Indication Treatment as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Orphan Indication Treatment Sales by Region (2017-2022) & (K Units) Table 16. Global Orphan Indication Treatment Sales Market Share by Region (2017-2022) Table 17. Global Orphan Indication Treatment Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Orphan Indication Treatment Revenue Market Share by Region (2017-2022) Table 19. North America Orphan Indication Treatment Sales by Country (2017-2022) & (K Units) Table 20. North America Orphan Indication Treatment Sales Market Share by Country (2017-2022) Table 21. North America Orphan Indication Treatment Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Orphan Indication Treatment Revenue Market Share by Country (2017-2022) Table 23. Europe Orphan Indication Treatment Sales by Country (2017-2022) & (K Units) Table 24. Europe Orphan Indication Treatment Sales Market Share by Country (2017-2022) Table 25. Europe Orphan Indication Treatment Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Orphan Indication Treatment Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Orphan Indication Treatment Sales by Region (2017-2022) & (K Units) Table 28. Asia Pacific Orphan Indication Treatment Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Orphan Indication Treatment Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Orphan Indication Treatment Revenue Market Share by Region (2017-2022) Table 31. Latin America Orphan Indication Treatment Sales by Country (2017-2022) & (K Units) Table 32. Latin America Orphan Indication Treatment Sales Market Share by Country (2017-2022) Table 33. Latin America Orphan Indication Treatment Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Orphan Indication Treatment Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Orphan Indication Treatment Sales by Country (2017-2022) & (K Units) Table 36. Middle East and Africa Orphan Indication Treatment Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Orphan Indication Treatment Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Orphan Indication Treatment Revenue Market Share by Country (2017-2022) Table 39. Global Orphan Indication Treatment Sales by Type (2017-2022) & (K Units) Table 40. Global Orphan Indication Treatment Sales Market Share by Type (2017-2022) Table 41. Global Orphan Indication Treatment Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Orphan Indication Treatment Revenue Share by Type (2017-2022) Table 43. Global Orphan Indication Treatment Price by Type (2017-2022) & (US$/Unit) Table 44. Global Orphan Indication Treatment Sales (K Units) by Application (2017-2022) Table 45. Global Orphan Indication Treatment Sales Market Share by Application (2017-2022) Table 46. Global Orphan Indication Treatment Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Orphan Indication Treatment Revenue Share by Application (2017-2022) Table 48. Global Orphan Indication Treatment Price by Application (2017-2022) & (US$/Unit) Table 49. Bristol-Myers Squibb Corporation Information Table 50. Bristol-Myers Squibb Description and Business Overview Table 51. Bristol-Myers Squibb Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 52. Bristol-Myers Squibb Orphan Indication Treatment Product Table 53. Bristol-Myers Squibb Recent Developments/Updates Table 54. Roche Corporation Information Table 55. Roche Description and Business Overview Table 56. Roche Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 57. Roche Orphan Indication Treatment Product Table 58. Roche Recent Developments/Updates Table 59. Novartis Corporation Information Table 60. Novartis Description and Business Overview Table 61. Novartis Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 62. Novartis Orphan Indication Treatment Product Table 63. Novartis Recent Developments/Updates Table 64. Johnson & Johnson Corporation Information Table 65. Johnson & Johnson Description and Business Overview Table 66. Johnson & Johnson Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 67. Johnson & Johnson Orphan Indication Treatment Product Table 68. Johnson & Johnson Recent Developments/Updates Table 69. Pfizer Corporation Information Table 70. Pfizer Description and Business Overview Table 71. Pfizer Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 72. Pfizer Orphan Indication Treatment Product Table 73. Pfizer Recent Developments/Updates Table 74. Amgen Corporation Information Table 75. Amgen Description and Business Overview Table 76. Amgen Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 77. Amgen Orphan Indication Treatment Product Table 78. Amgen Recent Developments/Updates Table 79. Sanofi Corporation Information Table 80. Sanofi Description and Business Overview Table 81. Sanofi Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 82. Sanofi Orphan Indication Treatment Product Table 83. Sanofi Recent Developments/Updates Table 84. AstraZeneca Corporation Information Table 85. AstraZeneca Description and Business Overview Table 86. AstraZeneca Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 87. AstraZeneca Orphan Indication Treatment Product Table 88. AstraZeneca Recent Developments/Updates Table 89. Takeda Corporation Information Table 90. Takeda Description and Business Overview Table 91. Takeda Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 92. Takeda Orphan Indication Treatment Product Table 93. Takeda Recent Developments/Updates Table 94. Vertex Pharmaceuticals Corporation Information Table 95. Vertex Pharmaceuticals Description and Business Overview Table 96. Vertex Pharmaceuticals Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 97. Vertex Pharmaceuticals Orphan Indication Treatment Product Table 98. Vertex Pharmaceuticals Recent Developments/Updates Table 99. AbbVie Corporation Information Table 100. AbbVie Description and Business Overview Table 101. AbbVie Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 102. AbbVie Orphan Indication Treatment Product Table 103. AbbVie Recent Developments/Updates Table 104. Biogen Corporation Information Table 105. Biogen Description and Business Overview Table 106. Biogen Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 107. Biogen Orphan Indication Treatment Product Table 108. Biogen Recent Developments/Updates Table 109. Eli Lilly Corporation Information Table 110. Eli Lilly Description and Business Overview Table 111. Eli Lilly Orphan Indication Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 112. Eli Lilly Orphan Indication Treatment Product Table 113. Eli Lilly Recent Developments/Updates Table 114. Production Base and Market Concentration Rate of Raw Material Table 115. Key Suppliers of Raw Materials Table 116. Orphan Indication Treatment Distributors List Table 117. Orphan Indication Treatment Customers List Table 118. Orphan Indication Treatment Market Trends Table 119. Orphan Indication Treatment Market Drivers Table 120. Orphan Indication Treatment Market Challenges Table 121. Orphan Indication Treatment Market Restraints Table 122. Global Orphan Indication Treatment Sales Forecast by Type (2023-2028) & (K Units) Table 123. Global Orphan Indication Treatment Sales Market Share Forecast by Type (2023-2028) Table 124. Global Orphan Indication Treatment Revenue Forecast by Type (2023-2028) & (US$ Million) Table 125. Global Orphan Indication Treatment Revenue Market Share Forecast by Type (2023-2028) Table 126. Global Orphan Indication Treatment Sales Forecast by Application (2023-2028) & (K Units) Table 127. Global Orphan Indication Treatment Sales Market Share Forecast by Application (2023-2028) Table 128. Global Orphan Indication Treatment Revenue Forecast by Application (2023-2028) & (US$ Million) Table 129. Global Orphan Indication Treatment Revenue Market Share Forecast by Application (2023-2028) Table 130. Global Orphan Indication Treatment Sales Forecast by Region (2023-2028) & (K Units) Table 131. Global Orphan Indication Treatment Sales Market Share Forecast by Region (2023-2028) Table 132. Global Orphan Indication Treatment Revenue Forecast by Region (2023-2028) & (US$ Million) Table 133. Global Orphan Indication Treatment Revenue Market Share Forecast by Region (2023-2028) Table 134. Research Programs/Design for This Report Table 135. Key Data Information from Secondary Sources Table 136. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Orphan Indication Treatment Figure 2. Global Orphan Indication Treatment Market Share by Type in 2021 & 2028 Figure 3. Biologics Product Picture Figure 4. Non-Biologics Product Picture Figure 5. Global Orphan Indication Treatment Market Share by Application in 2021 & 2028 Figure 6. Hospital Pharmacy Figure 7. Retail Pharmacy Figure 8. Online Sales Figure 9. Global Orphan Indication Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 10. Global Orphan Indication Treatment Market Size (2017-2028) & (US$ Million) Figure 11. Global Orphan Indication Treatment Sales (2017-2028) & (K Units) Figure 12. Orphan Indication Treatment Sales Share by Manufacturers in 2021 Figure 13. Global Orphan Indication Treatment Revenue Share by Manufacturers in 2021 Figure 14. The Global 5 and 10 Largest Orphan Indication Treatment Players: Market Share by Revenue in 2021 Figure 15. Orphan Indication Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 16. Global Orphan Indication Treatment Sales Market Share by Region (2017-2022) Figure 17. Global Orphan Indication Treatment Sales Market Share by Region in 2021 Figure 18. Global Orphan Indication Treatment Revenue Market Share by Region (2017-2022) Figure 19. Global Orphan Indication Treatment Revenue Market Share by Region in 2021 Figure 20. United States Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 21. Canada Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 22. Germany Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 23. France Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 24. U.K. Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. Italy Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. Russia Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. China Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. Japan Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. South Korea Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. India Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. Australia Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. China Taiwan Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Indonesia Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. Thailand Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Malaysia Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Mexico Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Brazil Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Argentina Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Turkey Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Saudi Arabia Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. UAE Orphan Indication Treatment Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Sales Market Share of Orphan Indication Treatment by Type (2017-2022) Figure 43. Manufacturing Cost Structure of Orphan Indication Treatment Figure 44. Manufacturing Process Analysis of Orphan Indication Treatment Figure 45. Orphan Indication Treatment Industrial Chain Analysis Figure 46. Channels of Distribution Figure 47. Distributors Profiles Figure 48. Bottom-up and Top-down Approaches for This Report Figure 49. Data Triangulation Figure 50. Key Executives Interviewed

Bristol-Myers Squibb Roche Novartis Johnson & Johnson Pfizer Amgen Sanofi AstraZeneca Takeda Vertex Pharmaceuticals AbbVie Biogen Eli Lilly